Johnson and Johnson 2005 Annual Report Download - page 52

Download and view the complete annual report

Please find page 52 of the 2005 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

PAGE 50 JOHNSON & JOHNSON 2005 ANNUAL REPORT
11. SEGMENTS OF BUSINESS(1) AND GEOGRAPHIC AREAS
Sales to Customers(2)
(Dollars in Millions) 2005 2004 2003
Consumer — United States $ 4,405 4,224 3,968
International 4,691 4,109 3,463
Total 9,096 8,333 7,431
Pharmaceutical — United States 14,478 14,960 13,271
International 7,844 7,168 6,246
Total 22,322 22,128 19,517
Medical Devices and Diagnostics— United States 9,494 8,586 8,035
International 9,602 8,301 6,879
Total 19,096 16,887 14,914
Worldwide total $50,514 47,348 41,862
Operating Profit Identifiable Assets
(Dollars in Millions) 2005(5) 2004(6) 2003(7) 2005 2004 2003
Consumer $ 1,667 1,514 1,393 $ 6,275 6,142 5,371
Pharmaceutical 6,610 7,608 5,896 16,091 16,058 15,001
Medical Devices and Diagnostics 5,418 4,091 3,370 16,540 15,805 16,082
Segments total 13,695 13,213 10,659 38,906 38,005 36,454
Less: Expenses not allocated to segments(3) 39 375 351
General corporate(4) 19,119 15,312 11,809
Worldwide total $13,656 12,838 10,308 $58,025 53,317 48,263
Additions to Property, Depreciation and
Plant & Equipment Amortization
(Dollars in Millions) 2005 2004 2003 2005 2004 2003
Consumer $ 321 227 229 $ 232 222 246
Pharmaceutical 1,388 1,197 1,236 918 1,008 765
Medical Devices and Diagnostics 785 630 639 821 769 761
Segments total 2,494 2,054 2,104 1,971 1,999 1,772
General corporate 138 121 158 122 125 97
Worldwide total $2,632 2,175 2,262 $2,093 2,124 1,869
Sales to Customers(2) Long-Lived Assets(8)
(Dollars in Millions) 2005 2004 2003 2005 2004 2003
United States $28,377 27,770 25,274 $15,355 14,324 14,367
Europe 12,187 11,151 9,483 5,646 6,142 5,193
Western Hemisphere excluding U.S. 3,087 2,589 2,236 957 748 772
Asia-Pacific, Africa 6,863 5,838 4,869 596 620 605
Segments total 50,514 47,348 41,862 22,554 21,834 20,937
General corporate 451 444 448
Other non long-lived assets 35,020 31,039 26,878
Worldwide total $50,514 47,348 41,862 $58,025 53,317 48,263
(1) See Note 1 for a description of the segments in which the Company operates.
(2) Export sales and intersegment sales are not significant. In 2005, the Company did not have a customer that represented 10% of total revenues. Sales to our top
distributors accounted for 10.2% and 10.0% of total revenues in 2004 and 10.5% of total revenues in 2003.
(3) Amounts not allocated to segments include interest (income)/expense, minority interest and general corporate (income)/expense.
(4) General corporate includes cash and marketable securities.
(5) Includes $302 million and $60 million of In-Process Research and Development (IPR&D) for the Pharmaceutical and Medical Devices and Diagnostics
segments, respectively.
(6) Includes $18 million of IPR&D in the Medical Devices and Diagnostics segment.
(7) Includes $737 million of IPR&D in the Pharmaceutical segment and $181 million of IPR&D and $230 million of an arbitration ruling on stent patents in the Medical
Devices and Diagnostics segment.
(8) Long-lived assets include property, plant and equipment, net for 2005, 2004 and 2003 of $10,830, $10,436 and $9,846, respectively, and intangible assets, net for
2005, 2004 and 2003 of $12,175, $11,842 and $11,539, respectively.